FIELD: pharmaceutics and medicine.
SUBSTANCE: method of increasing bone mass in a subject having low bone mass, which is a symptom of congenital leptin deficiency from which the subject suffers, including the administration of a pharmaceutical composition containing an antibody or an antigen-binding fragment that binds the receptor human leptin (LEPR) and activate LEPR-mediated signalling, containing a heavy chain variable region (HCVR), which contains HCDR1, HCDR2 and HCDR3 HCVR containing the amino acid sequence of SEQ ID NO: 26; and a light chain variable region (LCVR), which contains LCDR1, LCDR2 and LCDR3 LCVR, containing the amino acid sequence of SEQ ID NO: 10, and a pharmaceutically acceptable carrier or diluent to the subject in need thereof.
EFFECT: increase of bone mass in a subject having low bone mass, which is a symptom of congenital leptin deficiency.
4 cl, 27 dwg, 24 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR INCREASING BODY WEIGHT AND LEAN MUSCLE MASS USING LEPTIN RECEPTOR ANTAGONISTS, GDF8 AND ACTIVIN A | 2019 |
|
RU2818832C2 |
| METHODS FOR TREATMENT OF SEVERE INSULIN RESISTANCE BY INTERRUPTING GLUCAGON RECEPTOR SIGNAL TRANSMISSION | 2017 |
|
RU2772508C2 |
| ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA, AND COMPOSITIONS THEREOF, COMBINATIONS AND METHODS OF USING | 2015 |
|
RU2720282C1 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| ANTI-MET ANTIBODIES AND THEIR USE | 2017 |
|
RU2765267C2 |
| COMBINATION OF ANTIBODY AGAINST HGFR AND HEGFR FOR TREATMENT OF TUMOR AND/OR METASTASIS | 2019 |
|
RU2788606C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
